NDC 73441-062
Aphexda 62 mg per 1.7 mL injection, powder, lyophilized, for solution
On the label: Gamida Cell Inc..
Where it's made
| Factory | Where | Role | Last FDA inspection |
|---|---|---|---|
| BioConnection B.V. | Oss, Netherlands | Makes it | Problems found, fixed voluntarilyJan 10, 2025 · 1 inspection |
| Polypeptide Laboratories San Diego, LLC | San Diego, CA, United States | Makes the active ingredient and tests it | Problems found, fixed voluntarilyMay 15, 2025 · 7 inspections |
| ALS Group USA, Corp. | Torrance, CA, United States | Tests it | Problems found, fixed voluntarilyJun 5, 2023 · 5 inspections |
| Almac Pharma Services Limited | Craigavon, United Kingdom | Tests it, packages it and labels it | Problems found, fixed voluntarilyNov 28, 2025 · 8 inspections |
| BioChem Labor für biologische und chemische Analytik GmbH | Karlsruhe, Germany | Tests it | No problems foundMar 23, 2022 · 4 inspections |
| Element Materials Technology Pharma US LLC | Santa Fe Springs, CA, United States | Tests it | No problems foundMar 28, 2025 · 8 inspections |
| Eurofins Biopharma Product Testing Leiden B.V. | Location not on file | Tests it | Not inspected on record |
| PHARBIL Pharma GmbH | Bielefeld, Germany | Tests it | Problems found, fixed voluntarilyJun 18, 2024 · 3 inspections |
| PPD Development, L.P. | Middleton, WI, United States | Tests it | Problems found, fixed voluntarilySep 25, 2025 · 6 inspections |
| Polypeptide Laboratories Inc | Torrance, CA, United States | Tests it | Problems found, fixed voluntarilyMay 10, 2024 · 9 inspections |
Product details
- Generic drug
- Motixafortide: every company that makes it
- Form
- injection, powder, lyophilized, for solution, subcutaneous
- Strength
- 62 mg per 1.7 mL
- Approval
- NDA NDA217159
- On the market since
- Jun 15, 2025
- Package NDCs
73441-062-01- Official label
- DailyMed (National Library of Medicine), updated Jun 4, 2026
Got it by mail or from a pharmacy you don't know? Look the pharmacy up on Who Filled My Rx?